+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Gram-positive Bacterial Infections Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4896260
  • Report
  • June 2020
  • Region: Global
  • 114 Pages
  • Mordor Intelligence


  • AstraZeneca
  • Cipla Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Inc.
  • Merck & Co. Inc.
  • Novartis AG
The major factor driving the growth of the Gram-positive Bacterial Infections market is the increasing prevalence of the infections because of gram-positive bacteria. Pneumonia is a type of Gram-positive Bacterial Infection that affects the lungs. According to WHO, pneumonia killed 808 694 children under the age of 5 in 2017, accounting for 15% of all deaths of children under five years old. Pneumonia affects children and families everywhere but is most prevalent in South Asia and Sub-Saharan Africa.

Additionally, increasing product approvals for the treatment of the infections, the rising development of Anti-MRSA drugs are also boosting the market growth globally. In October 2018, Paratek Pharmaceuticals, Inc. received U.S. FDA approval for its NUZYRA (Omadacycline)injection, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). However, antibiotic resistance is the major restraint that is hampering the growth of the market.

Key Market Trends

Cephalosporins Segment is Found Holding a Significant Market Share During the Forecast Period

Cephalosporins are beta-lactam antibiotics that inhibit the synthesis of peptidoglycan, present in the cell wall of the bacteria. According to the World Health Organization (WHO), this group of antibiotics is considered critically important to human medicine. The cephalosporins are indicated for the treatment of infections caused by Gram-positive bacteria in certain circumstances. These include selected patients with endocarditis, osteomyelitis, septic arthritis, and cellulitis. They are also used as alternatives to the penicillins in penicillin-allergic patients and for 'mixed' infections caused by Gram-positive organisms.

Cephalosporin has a large share in the antibiotics market, which is partly due to overprescription, and also due to the fact that it is the most widely explored family of antibiotics with over five generations of cephalosporins that have already been developed. Additionally, the companies are involved in the strategic development of new products.

North America is Found Dominating the Gram-positive Bacterial Infections Market

North America and Europe are the major markets in the Gram-positive Bacterial Infections globally, due to the high prevalence of various types of gram-positive bacterial infections and associated diseases.

In the United States, antibiotic use among older adults increased, after insurance coverage was expanded through Medicare Part D, particularly, of broad-spectrum antibiotics. Increasing product launches are anticipated to drive the gram-positive bacterial infections market in the North America region. For instance, in March 2017, Pfizer launched a combination of Avibactam and Ceftazidime drug Zavicefta, for the treatment of intraabdominal infections.

Competitive Landscape

The gram-positive Bacterial Infections market is moderately competitive. The market is comprised of many small and large market players. Some of the market players are GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., etc. among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • AstraZeneca
  • Cipla Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Inc.
  • Merck & Co. Inc.
  • Novartis AG

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 RisingPrevalence of Gram-positive Bacterial Infections
4.2.2 Increasing Number of Drug Approvals
4.3 Market Restraints
4.3.1 Antibiotic Resistance
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Drug Type
5.1.1 b-Lactam Antimicrobials
5.1.2 Fluoroquinolones
5.1.3 Penicillin
5.1.4 Cephalosporins
5.1.5 RNA Immunoprecipitation (RIP)
5.1.6 Vaccine
5.1.7 Others Drugs
5.2 By Disease
5.2.1 Pneumonia
5.2.2 Sepsis
5.2.3 Pharyngitis
5.2.4 Methicillin-resistant Staphylococcus aureus (MRSA) Infections
5.2.5 Endocarditis
5.2.6 Meningitis
5.2.7 Other Diseases
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 GlaxoSmithKline Plc
6.1.2 Johnson & Johnson Inc.
6.1.3 Merck & Co. Inc.
6.1.4 Pfizer Inc.
6.1.5 AstraZeneca
6.1.6 Cumberland Pharmaceuticals
6.1.7 Novartis AG
6.1.8 Sanofi SA
6.1.9 Sun Pharmaceutical Industries Ltd.
6.1.10 Cipla Ltd.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • GlaxoSmithKline Plc
  • Johnson & Johnson Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • AstraZeneca
  • Cumberland Pharmaceuticals
  • Novartis AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
Note: Product cover images may vary from those shown